TD Cowen maintains Buy on MetLife, raises target to $105
TD Cowen analyst Andrew Kligerman maintained a Buy rating on MetLife and raised the price target to $105 from $87, reflecting an updated valuation outlook.
*this image is generated using AI for illustrative purposes only.
TD Cowen analyst Andrew Kligerman has maintained a Buy rating on MetLife (NYSE: MET) and raised the price target to $105 from $87. The adjustment reflects an updated valuation outlook for the insurance provider. The revised target indicates potential upside from the previous estimate of $87.
Rating and Target Details
The brokerage's stance remains positive on the stock, retaining the Buy designation. The new price target of $105 represents an increase over the prior $87 level.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $87 |
| New Price Target | $105 |
What specific factors drove the significant increase in MetLife's valuation outlook?
How might this price target revision influence investor sentiment toward the insurance sector?
What are the potential risks that could prevent MetLife from reaching the new $105 target?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
